Epidural Abscess Treatment Market Report 2026

The epidural abscess treatment market size has grown strongly in recent years. It will grow from $43.78 billion in 2025 to $46.6 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to spinal infection incidence, delayed diagnosis risks, antibiotic availability, hospital neurosurgery capacity, infectious disease burden.

The epidural abscess treatment market size is expected to see strong growth in the next few years. It will grow to $62.27 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advanced imaging access, early intervention protocols, antimicrobial innovation, hospital infrastructure expansion, clinician awareness. Major trends in the forecast period include increased use of early diagnostic imaging, rising reliance on broad-spectrum antibiotics, growth in surgical intervention rates, expansion of hospital-based infection care, focus on preventing neurological complications.

The increasing prevalence of neurological disorders is expected to drive the growth of the epidural abscess treatment market in the coming years. Neurological disorders are medical conditions that affect the nervous system, including the brain, spinal cord, and nerves. Common neurological disorders include acute spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and others. Epidural abscess treatment involves prompt surgical drainage of the abscess along with antibiotic therapy to prevent spinal cord and nerve compression and relieve pressure on the nervous system. For example, in April 2025, the Alzheimer's Association, a US-based nonprofit organization, reported that 7.2 million people aged 65 and older are living with Alzheimer’s disease in 2025. Additionally, total annual costs for caring for individuals with Alzheimer’s and other dementias (excluding unpaid care) are projected to reach $384 billion in 2025. Therefore, the growing prevalence of neurological disorders is driving the epidural abscess treatment market.

Rising intravenous drug use is expected to support the growth of the epidural abscess treatment market going forward. Intravenous drug use involves injecting drugs directly into the bloodstream using a needle and syringe. This practice can lead to epidural abscesses when contaminated injection equipment or drugs introduce bacteria or pathogens into the bloodstream, increasing the incidence of the condition and creating demand for specialized treatments and preventive programs. For instance, in June 2025, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that methamphetamine (53%) was the most commonly injected drug nationally in 2023. The proportion of participants reporting methamphetamine as the drug they injected most often was 56% in 2023 and 59% in 2024. Therefore, the rise in intravenous drug use is driving the growth of the epidural abscess treatment market.

The increase in healthcare expenditures is expected to propel the growth of the epidural abscess treatment market in the coming years. Healthcare expenditures encompass all costs related to providing health services, family planning, nutrition programs, and emergency health support. Higher healthcare spending supports the development of more effective therapies and medical technologies for epidural abscess treatment. For instance, in May 2023, the Office for National Statistics, a UK-based authority, reported that healthcare expenditure in the UK reached approximately $362.08 billion (£292 billion) in 2023, reflecting a nominal increase of 5.6%. Healthcare spending as a percentage of GDP slightly decreased to 10.9% in 2023 from 11.1% in 2022. Therefore, rising healthcare expenditures are driving the growth of the epidural abscess treatment market.

Major companies operating in the epidural abscess treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma, Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Kyowa Hakko Kirin Co. Ltd., Hikma Pharmaceuticals plc, Intas Pharmaceuticals Limited, Alembic Limited, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals.

North America was the largest region in the epidural abscess treatment market in 2025. The regions covered in the epidural abscess treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epidural abscess treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the epidural abscess treatment market by increasing costs of imported antibiotics, imaging equipment, and surgical supplies. Hospitals and specialty clinics in developed regions are most affected due to dependence on imported medical technologies. These tariffs raise treatment expenses but encourage domestic production of infection management solutions.

The epidural abscess treatment market research report is one of a series of new reports that provides epidural abscess treatment market statistics, including epidural abscess treatment industry global market size, regional shares, competitors with a epidural abscess treatment market share, detailed epidural abscess treatment market segments, market trends and opportunities, and any further data you may need to thrive in the epidural abscess treatment industry. This epidural abscess treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epidural abscess treatment involves managing a rare condition characterized by an infection in the space between the bones of the skull or spine and the membranes surrounding the brain and spinal cord. This treatment aims to relieve symptoms, slow disease progression, and prevent complications.

The main types of epidural abscesses are intracranial and intraspinal. An intracranial epidural abscess is an infection located between the bones of the skull and the membranes covering the brain and spinal cord. Treatment options include antifungals, antibiotics, and surgical interventions, and these are utilized by various end users such as hospitals, pharmacies, specialty clinics, and others.

The epidural abscess treatment market consists of revenues earned by entities by providing surgical intervention, myelography, magnetic resonance imaging (MRI) and computed tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The epidural abscess treatment market also includes sales of vancomycin, gentamicin and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.